

# Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics.

*TOKYO and KANSAS CITY, KANSAS, December 13, 2017 /PRNewswire/* -- Kangen Pharmaceuticals (“Kangen”) and KC Specialty Therapeutics (“KCST”) today announced that Kangen has reached an agreement with KCST and agreed to acquire the assets of KCST. Kangen intends to retain operations in Kansas City, Kansas, USA, with expansions in Japan and the US.

"This is a significant milestone for both Kangen and KCST. This acquisition provides Kangen with a unique opportunity for growth in two major markets – the US and Japan" said Mr. Norihiro Hirota, Chairperson and President of Kangen.

KCST has an existing portfolio of products focused on niche indications, and orphan drug designations. This acquisition also creates for Kangen an expanded network of affiliates and alliances in Asia and Europe, where Kangen will further expand strategic business alliances and portfolio of branded pharmaceuticals.

Diana Wood, CEO of KCST added, "This acquisition brings together complementary strengths of Kangen and KCST and also enhances our strategic position and value with our partners in Japan". Diana Wood will take on the additional role of the President of Kangen, while Mr. Hirota will retain the chairperson position.

## **About Kangen**

Kangen Pharmaceuticals Co., Ltd. was founded in 2005 by Mr. Hirota. Kangen, formerly known as Stason Pharma Japan, has been instrumental in establishing strategic relationships between KCST and its partners in Japan, now with several ongoing projects in various stages of the FDA review process. For more information, please visit: [www.Kangenpharma.com](http://www.Kangenpharma.com)

## **About KC Specialty**

KC Specialty Therapeutics, LLC is a US-based pharmaceutical company focused on the development of quality therapeutics for niche markets, and unmet medical need such as for orphan indications. KC Specialty is headquartered in Kansas City, KS and was founded in 2012 as a subsidiary of Stason Pharmaceuticals, which entered the US market in 1994. Under the management of CEO, Diana Wood, KC Specialty has extensive expertise in brand drug development, and navigation of complex regulatory pathways, which will compliment Kangen’s strategic alliances, worldwide. For more information, please visit: [www.KCSpecialty.com](http://www.KCSpecialty.com)